23andMe DNA Data: Anne Wojcicki’s Bid
- Anne Wojcicki, the company's co-founder, is attempting to regain control of its assets, including a vast genetic database.
- Wojcicki, who stepped down as CEO in March, submitted a $305 million bid through her nonprofit, TTAM Research Institute.
- Following this news, 23andMe's stock value increased by over 24%. Representatives from 23andMe, TTAM, and Regeneron agreed to reopen the sale process.The next auction will commence with TTAM's...
Anne Wojcicki is battling to reclaim the 23andMe DNA database, placing a meaningful $305 million bid amidst bankruptcy proceedings. This move follows Regeneron‘s prior $256 million agreement,triggering a second auction for the company’s assets. 23andMe shares surged over 24% following the news, signaling investor optimism. The competitive bidding highlights the substantial value of the primary_keyword, the 23andMe genetic data. The secondary_keyword, the user database, is at stake. News Directory 3 reports on the ongoing developments in the race for 23andMe’s future, its trove of genetic information, and the implications for medical research alongside consumer privacy. Discover what’s next as the auction unfolds.
Wojcicki Bids to Reclaim 23andMe DNA database in Bankruptcy Auction
Updated June 06, 2025
A new twist has emerged in the 23andMe bankruptcy saga. Anne Wojcicki, the company’s co-founder, is attempting to regain control of its assets, including a vast genetic database. this advancement follows Regeneron’s initial purchase agreement for $256 million.
Wojcicki, who stepped down as CEO in March, submitted a $305 million bid through her nonprofit, TTAM Research Institute. The revelation occurred during a court hearing in st. Louis, Mo., prompting a second auction.
Following this news, 23andMe’s stock value increased by over 24%. Representatives from 23andMe, TTAM, and Regeneron agreed to reopen the sale process.The next auction will commence with TTAM’s $305 million offer, exceeding Regeneron’s original bid by nearly $50 million.
Founded in 2006,23andMe gained popularity with its ancestry kits. The company went public in 2021, reaching a valuation of $6 billion by year’s end. However, financial struggles soon followed. Revenue generation beyond initial DNA kit purchases proved challenging, and a important data breach in 2023 exposed approximately 7 million users’ data, leading to a class-action lawsuit. The company subsequently filed for Chapter 11 bankruptcy.
Concerns arose regarding the future of 23andMe’s extensive user DNA database. State attorneys general urged users to delete their data. Regeneron pledged to uphold privacy laws upon its initial acquisition, a commitment TTAM also intends to honor if successful in the upcoming auction. Regeneron planned to use the 23andMe data to accelerate medical research.
The upcoming auction will begin with TTAM’s $305 million bid. Regeneron must then offer a higher bid, starting at $315 million. TTAM will have two hours to respond with a final proposal before Regeneron submits its ultimate bid. The losing bidder will receive a $10 million breakup fee.
Brian Walsh, U.S. Bankruptcy Judge, called the negotiated terms a “very positive development” for equity holders.
What’s next
The second auction will determine the future of 23andMe’s assets and its vast DNA database. The outcome will impact medical research and consumer privacy.